RBMS3表达与上皮性卵巢癌临床病理特征及预后  

RBMS3 Expression and Its Correlation with Clinicopathological Features and Prognosis of Epithelial Ovarian Cancer

作　　者：邢瑞丽 印天 范方田 张颖[1] 张庆松[1] 杨波[1] XING Rui-li;YIN Tian;FAN Fang-tian;ZHANG Ying;ZHANG Qing-song;YANG Bo(Department of Gynecology,The First Affiliated Hospital of Bengbu Medical College,Bengbu 233000,China;College of Pharmacy,Bengbu Medical College,Bengbu 233000,China;Anhui Engineering Technology Research Center of Biochemical Pharmaceutical,Bengbu 233000,China)

机构地区：[1]蚌埠医学院第一附属医院妇瘤科,安徽蚌埠233000 [2]蚌埠医学院药学院,安徽蚌埠233000 [3]安徽省生物化学药物工程研究中心,安徽蚌埠233000

出　　处：《中山大学学报（医学科学版）》2023年第2期277-285,共9页Journal of Sun Yat-Sen University:Medical Sciences

基　　金：安徽省高等学校自然科学研究项目(KJ2021A0727);安徽省蚌埠医学院自然科学重点项目(2020byzd063)。

摘　　要：[目的]探讨RNA结合基序单链相互作用蛋白3(RBMS3)在上皮性卵巢癌(EOC)组织中的表达,及其与EOC组织的临床病理特征和预后的关系。[方法]选取蚌埠医学院第一附属医院2015年1月~2019年12月经术后病理证实的110例EOC石蜡包埋组织及73例上皮性卵巢良性肿瘤石蜡包埋组织,利用抗RBMS3的多克隆抗体进行免疫组织化学染色(IHC),检测各组织中RBMS3的表达情况,并分析RBMS3的表达与EOC临床病理参数及预后的相关性。[结果]在EOC组织与上皮性卵巢良性肿瘤组织中RBMS3均表达,而RBMS3在EOC组织中的表达水平明显低于其在上皮性卵巢良性肿瘤组织中的表达水平(P<0.05);在EOC组织中的表达水平与其国际妇产科联合会的分期(FIGO分期)、组织学分级、CEA水平及生存状况有关(P<0.05);Kaplan-Meier生存曲线表明:RBMS3的低表达与EOC患者的无疾病进展期(PFS)和总生存期(OS)的降低均有关(P<0.05);单因素分析结果示:RBMS3表达、FIGO分期、残余病灶大小、肠道转移、腹腔种植与EOC患者的OS相关(P<0.05);多因素分析示:RBMS3低表达及肠道转移是EOC患者预后不良的独立危险因素(P<0.05)。[结论]RBMS3在EOC组织中低表达,且与EOC患者的不良预后密切相关。因此,RBMS3可能在EOC组织中发挥抑癌基因作用,且RBMS3是一种有用的EOC独立预后标记物,可能为EOC的靶向治疗提供一种潜在靶点。[Objective]To investigate the expression of RNA binding motif single stranded interacting protein 3(RBMS3)in epithelial ovarian cancer(EOC)tissues and its relationship with the clinicopathological features and progno⁃sis of EOC.[Methods]The study enrolled the paraffin-embedded tissues from 110 EOC cases and 73 benign epithelial ovarian tumor cases pathologically diagnosed in the first affiliated Hospital of Bengbu Medical College from January 2015 to December 2019.By using anti-RBMS3 polyclonal antibody,the immunohistochemical staining was employed to detect RBMS3 expression in the tissues and then its correlation with the clinicopathological parameters and prognosis of EOC was analyzed.[Results]RBMS3 was expressed in both EOC and benign epithelial ovarian tumor tissues.RBMS3 expression in EOC tissues,significantly related with International Federation of Gynecology and Obstetrics(FIGO)stage,histological grade,CEA levels and survival status,was significantly lower than that in benign epithelial ovarian tumor tissues(P<0.05).Kaplan-Meier survival curve showed that low RBMS3 expression in EOC patients was correlated with decreased progression-free survival(PFS)and overall survival(OS)(P<0.05).Univariate analysis showed that RBMS3 expression,FIGO stage,residual lesion size,intestinal metastasis and intraperitoneal implantation were associated with OS of EOC pa⁃tients(P<0.05);multivariate analysis showed that low RBMS3 expression and intestinal metastasis were independent risk factors for poor prognosis in EOC patients(P<0.05).[Conclusions]RBMS3 is expressed at low levels in EOC tissues,which is closely related to poor prognosis of EOC patients.RBMS3 may function as a tumor suppressor gene in EOC tissues and can be used as an EOC-independent prognostic marker for targeted therapy against EOC.

关 键 词：上皮性卵巢癌 RBMS3 临床病理特征 预后 

分 类 号：R711.75[医药卫生—妇产科学]